难治性抑郁症与患者结局及医疗资源利用的全人群研究
TRD与更多住院床日、更多误工日、更高共病负担、更高蓄意自伤及全因死亡率相关,且换药间隔长于指南推荐。
要点
- 全人群抑郁发作中约11%符合TRD标准,中位进展至TRD时间为552天。
- TRD发作12个月内住院床日和误工日均显著高于匹配的非TRD发作。
- TRD患者全因死亡率10.7/1000人年,高于非TRD的8.7/1000人年(HR 1.23)。
核心结论
- 在包含精神科与非精神科诊疗数据的全人群队列中,TRD是MDD的常见变异型,给患者和社会带来高疾病负担。
- 从启动新抗抑郁治疗到下一次启动的中位时间长于现行治疗指南推荐,提示抑郁照护可更结构化和及时。
研究设计与样本
- 基于斯德哥尔摩MDD队列的 population-based 观察性队列研究,评估2010至2017年MDD发作。
- TRD定义为连续≥3种抗抑郁治疗;数据分析时间为2020年8月至2022年5月。
主要发现
- TRD发作从MDD发作开始至TRD的中位时间为552天(IQR 294-932)。
- TRD发作在索引日期后12个月的平均住院床日为3.9天(95%CI 3.6-4.1),匹配非TRD发作为1.3天(95%CI 1.2-1.4)。
- TRD发作平均误工日为132.3天(95%CI 129.5-135.1),匹配非TRD发作为58.7天(95%CI 56.8-60.6)。
- 焦虑、应激、睡眠障碍和物质使用障碍在TRD发作中均更常见,蓄意自伤在TRD发作中超过4倍常见。
- TRD患者全因死亡率为10.7/1000人年,非TRD患者为8.7/1000人年(HR 1.23;95%CI 1.07-1.41);MDD严重度(MADRS-S)是TRD最重要的预后因素(C指数=0.69)。
关键数值与推荐
- TRD判定标准为连续≥3种抗抑郁治疗。
- 从首次抗抑郁治疗至第二次、以及从第二次至第三次治疗的中位时间分别为165天和197天。
- 选择性5-羟色胺再摄取抑制剂是所有治疗步骤中最常见的抗抑郁药类别;5907例患者(46.2%)在启动第三种药物治疗前曾接受心理治疗。
临床怎么用
- 对MDD患者应关注TRD风险,尤其抑郁严重度较高者,并及早评估治疗反应。
- 换药间隔可能长于指南推荐,临床可考虑更结构化和及时的抑郁照护流程。
- TRD患者需综合管理共病(焦虑、应激、睡眠、物质使用)及自伤风险,并关注医疗资源使用与误工负担。
局限性
- 原文未报告研究局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The totality of the societal and individual impact of treatment-resistant depression (TRD) is unknown, as is the potential to prognosticate TRD. The generalizability of many observational studies on TRD is limited. OBJECTIVE: To estimate the burden of TRD in a large population-wide cohort in an area with universal health care by including data from both health care types (psychiatric and nonpsychiatric) and, further, to develop a prognostic model for clinical use. DESIGN, SETTING, AND PARTICIPANTS: This cohort study, a population-based observational study, assessed data from the Stockholm MDD Cohort for episodes of major depressive disorder (MDD) between 2010 and 2017 that fulfilled predefined criteria for TRD (≥3 consecutive antidepressant treatments). Data analysis was performed from August 2020 to May 2022. MAIN OUTCOMES AND MEASURES: Outcomes were psychiatric and nonpsychiatric comorbid conditions, antidepressant treatments, health care resource utilization, lost workdays, all-cause mortality, and intentional self-harm and, in the prognostic model, TRD. RESULTS: A total of 158 169 unipolar MDD episodes (in 145 577 patients) were identified between January 1, 2012, and December 31, 2017 (64.7% women; median [IQR] age, 42 years [30-56]). Of these, 12 793 episodes (11%) fulfilled criteria for TRD. The median (IQR) time from the start of MDD episode to TRD was 552 days (294-932). Selective serotonin reuptake inhibitor was the most common class of antidepressant treatment in all treatment steps, and 5907 patients (46.2%) received psychotherapy at some point before initiation of the third pharmacological antidepressant treatment. Compared with matched non-TRD episodes, TRD episodes had more inpatient bed-days (mean, 3.9 days; 95% CI, 3.6-4.1, vs 1.3 days; 95% CI, 1.2-1.4) and more lost workdays (mean, 132.3 days; 95% CI, 129.5-135.1, vs 58.7 days; 95% CI, 56.8-60.6) 12 months after the index date. Anxiety, stress, sleep disorder, and substance use disorder were all more common comorbid conditions in TRD episodes. Intentional self-harm was more than 4 times more common in TRD episodes. The all-cause mortality rate for patients with MDD with TRD episodes was 10.7/1000 person-years at risk, compared with 8.7/1000 person-years at risk for patients with MDD without TRD episodes (hazard ratio, 1.23; 95% CI, 1.07-1.41). Median time from start of the first antidepressant treatment to start of the second, and from start of the second antidepressant treatment to start of the third, was 165 and 197 days, respectively. The severity of MDD, defined using the self-rating Montgomery-Åsberg Depression Rating Scale (MADRS-S) at time of MDD diagnosis, was found to be the most important prognostic factor for TRD (C index = 0.69). CONCLUSIONS AND RELEVANCE: In this cohort study, TRD was a common variant of MDD when including patients from both health care types, which is associated with a high disease burden for both patients and society. The median time between initiation of new antidepressant treatments was longer than recommended in current treatment guidelines, suggesting room for more structured and timely depression care.
引用
- Lundberg J, Cars T, Lööv SÅ, et al. Association of Treatment-Resistant Depression With Patient Outcomes and Health Care Resource Utilization in a Population-Wide Study. JAMA Psychiatry. 2023. PMID: 36515938. doi:10.1001/jamapsychiatry.2022.3860
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。